<DOC>
	<DOC>NCT02287597</DOC>
	<brief_summary>This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus Avastin (bevacizumab). There will be no additional diagnostic or therapeutic procedures required by this study, apart from those performed in everyday clinical practice for second-line treatment of mCRC in Croatia.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Written informed consent Age &gt;/=18 years Metastatic colorectal cancer (mCRC) previously treated with systemic treatment for advanced disease containing Avastin and chemotherapy; firstline Avastin received according to the Summary of Product Characteristics (SmPC) First line progressionfree survival (PFS) &gt;6 months Eligible for secondline chemotherapy regimen Period between first progression and start of second line treatment with Avastin and chemotherapy &lt;/=6 weeks Contraindications, warnings and precautions for use specified in the Avastin SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>